July 22, 2009--Minster Pharmaceuticals plc, the drug development company specialising in neurological and psychiatric disorders, is pleased to announce that it has just received confirmation that it has successfully filed a divisional application in the USA covering a method of adjunct therapy using sabcomeline to treat a psychotic disorder, more particularly to treat the negative and cognitive symptoms associated with schizophrenia. Based on an opinion obtained from Minster’s US attorney, the Company has confidence that these claims are patentable and should therefore be granted.
the details can be read here.
No comments:
Post a Comment